We examined the activities of peptidases in synovial fluid from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Dipeptidyl peptidase IV (DPP IV) activity was lower in synovial fluid from patients with RA, in contrast to the increase of DPP II activity in synovial fluid, as compared with OA. The DPP II/DPP IV ratio for synovial fluid was significantly higher in patients with RA than in patients with OA. A significant correlation was observed between the DPP II/DPP IV ratio for synovial fluid from patients with RA and the amount of C-reactive protein reaction. These results may be useful in the diagnosis of joint effusion of unknown origin.
The activity of dipeptidyl peptidase IV (EC 3.4.14.5) in human sera from normal controls and osteoporotic patients was assayed with Gly-Pro-4-methylcoumaryl-7-amide (Gly-Pro-MCA) as substrate, at pH 8.7. The mean normal value for the activity in serum of 120 healthy subjects (ages 20-86 y) was 54.0 (SE 0.9, range 34.3-81.6) U/L at 37 degrees C and differed slightly but significantly between the younger group (less than 50 y old) and those older than 50 y. Values for the younger men were slightly but significantly higher than for the older men. Overall, however, the enzyme activities in serum were above normal in patients with osteoporosis. In contrast, the activity of post-proline cleaving enzyme (PPCE) was not increased in serum from patients with osteoporosis, as determined with succinyl-Gly-Pro-4-methylcoumaryl-7-amide (Suc-Gly-Pro-MCA) as substrate. These results suggest that high activities of dipeptidyl peptidase IV in serum of patients with osteoporosis are probably related to its severity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.